Skip to content
zameds

Nicorette

Nicotine

Every registration of this product has been cancelled.

Loading the molecular structure
C10H14N2162.23 g/mol

3-[(2S)-1-Methylpyrrolidin-2-yl]pyridine

Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 89594.

Registration

Applicants
1
Registrations
6

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Johnson & Johnson (Pty) Ltd û East LondonCancelledNicorette5 mg, 10 mg, 15 mg, inhaler, 2 mg, 4 mg290150, 290151, 290152, 340329, P0187, P0188Not determinedNone

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Nicorette patch 5 MG

EACH 10 cm PATCH CONTAINS NICOTINE 8,3 mg

5 mgPatch29015029/34/150CancelledNot determinedNone
Nicorette patch 10 MG

EACH 20 cm PATCH CONTAINS NICOTINE 16,6 mg

10 mgPatch29015129/34/0151CancelledNot determinedNone
Nicorette patch 15 MG

EACH 30 cm PATCH CONTAINS NICOTINE 24.9 mg

15 mgPatch29015229/34/0152CancelledNot determinedNone
Nicorette inhaler

EACH CARTRIDGE CONTAINS NICOTINE 10,0 mg

Inhaler34032934/34/0329CancelledNot determinedNone
Nicorette 2 MG

EACH PIECE OF GUM CONTAINS NICOTINE RESIN COMPLEX EQUIVALENT TO NICOTINE 2 mg

2 mgP0187P/34/187CancelledNot determinedNone
Nicorette 4 MG

EACH PIECE OF GUM CONTAINS NICOTINE RESIN COMPLEX EQUIVALENT TO NICOTINE 4 mg

4 mgP0188P/34/188CancelledNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S3: Nicotine

    • when intended for human medicinal use as an aid to smoking cessation or as a substitute for a tobacco product (as defined in the Tobacco Products Control Act, 1993, as amended);
    • except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing not more than 4 mg nicotine per piece; (S0)
    • except when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths up to an including 21mg/ 24 hours or 25 mg/ 16 hours; (S1)
    • except when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths containing more than 21mg/ 24 hours or 25 mg/ 16 hours; (S2)
    • except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing more than 4 mg nicotine per piece; (S2)
    • except when registered as metered sprays containing not more than 1 mg per dose; (S1)
    • except when registered as oral solid dosage forms containing not more than 2 mg; (S2)
    • except when registered as inhalers containing not more than 10 mg per cartridge. (S2)

    Consolidated Schedules 06 July 2026, lines 4004 to 4027

  • S2: Nicotine

    • when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing more than 4mg nicotine per piece;
    • when registered as oral solid dosage forms containing 2mg or less;
    • when registered as inhalers containing 10mg or less per cartridge;
    • when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths containing more than 21mg/ 24 hours or 25 mg/ 16 hours;
    • except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing not more than 4mg nicotine per piece; (S0)
    • except when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths up to an including 21mg/ 24 hours or 25 mg/ 16 hours; (S1)
    • except when intended for human medicinal use as an aid to smoking cessation or as a substitute for a tobacco product (as defined in the Tobacco Products Control Act, 1993, as amended). (S3)

    Consolidated Schedules 06 July 2026, lines 2394 to 2415

  • S1: Nicotine

    • when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths up to an including 21mg/ 24 hours or 25 mg/ 16 hours;
    • except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing not more than 4 mg nicotine per piece; (S0)
    • except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing more than 4 mg nicotine per piece; (S2)
    • except when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths containing more than 21mg/ 24 hours or 25 mg/ 16 hours; (S2)
    • when registered as metered sprays containing not more than 1 mg per dose or less;
    • except when registered as oral solid dosage forms containing not more than 2 mg; (S2)
    • except when registered as inhalers containing not more than 10 mg per cartridge; (S2)
    • except when intended for human medicinal use as an aid to smoking cessation or as a substitute for a tobacco product (as defined in the Tobacco Products Control Act, 1993, as amended). (S3)

    Consolidated Schedules 06 July 2026, lines 890 to 917

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading...
Loading Wikipedia summary

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Research articles

Loading...
Loading PubMed articles